The Development of HIV Vaccines: Advances and Challenges
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "HIV Vaccines".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 42
Special Issue Editor
Interests: HIV accessory genes; HIV-related lipid dysregulation; HIV-related mechanisms of inflammation; HIV-infected cells; anti-HIV compounds; HIV-1 translocation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue aims to showcase research and emerging challenges in developing HIV vaccines. We invite original research articles, reviews, and perspectives that explore novel immunogens, innovative adjuvants, and advancements in vaccine delivery platforms. Submissions that focus on immune correlates of protection, strategies to elicit broadly neutralizing antibodies, and lessons learned from past vaccine trials are highly encouraged. We are particularly interested in studies that address advanced immunological concepts, including trained immunity, epigenetic reprogramming of innate responses, and the role of heterologous immunity in vaccine efficacy. Manuscripts discussing novel vaccine strategies, such as mRNA platforms, are encouraged, as are contributions that examine immune-metabolic regulation in vaccine-induced responses.
I look forward to receiving your contributions.
Prof. Dr. Michael Bukrinsky
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV vaccine
- trained immunity
- broadly neutralizing antibodies
- T-cell immunity
- epigenetic reprogramming
- immune metabolism
- systems immunology
- adjuvants
- mucosal immunity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
